Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma

Amit Roy, Prashant Gabani, Elizabeth J. Davis, Peter Oppelt, Emily Merfeld, Vicky L. Keedy, Imran Zoberi, John S.A. Chrisinger, Jeff M. Michalski, Brian Van Tine, Matthew B. Spraker

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Introduction: We compared clinical outcomes in patients with cutaneous angiosarcoma receiving concurrent paclitaxel-based chemoradiotherapy (CRT) vs. other modalities (Non-CRT). Materials and methods: Patients with non-metastatic cutaneous angiosarcoma diagnosed from 1998 to 2018 at two institutions were identified. In the CRT cohort, paclitaxel 80 mg/m2 weekly was given for up to 12 weeks and patients received radiotherapy (RT) during the final 6 weeks of chemotherapy. The RT dose was 50–50.4 Gy delivered in 1.8–2 Gy per fraction with an optional post-operative boost of 10–16 Gy. Kaplan-Meier and log-rank statistics were used to compare the outcomes between the two groups. P < 0.05 was considered statistically significant. Results: Fifty-seven patients were included: 22 CRT and 35 Non-CRT. The CRT cohort had more patients > 60 years (100% vs. 60%, p < 0.001) and tumors >5 cm (68.2% vs 54.3%, p = 0.023). The median follow-up was 25.8 (1.5–155.2) months. There was no significant difference in 2-year local control (LC), distant control (DC), or progression-free survival (PFS) between the two groups. The 2-year overall survival (OS) was significantly higher for the CRT cohort (94.1% vs. 71.6%, p = 0.033). Amongst the subset of patients in the CRT cohort who received trimodality therapy, the 2-year LC, DC, PFS, and OS was 68.6%, 100%, 68.6%, and 100%, respectively. Conclusion: The use of concurrent paclitaxel CRT demonstrates promising outcomes. Given these results, we are currently evaluating the safety and efficacy of this regimen in prospective, phase 2 trial (NCT 03921008).

Original languageEnglish
Pages (from-to)114-120
Number of pages7
JournalClinical and Translational Radiation Oncology
StatePublished - Mar 2021


  • Angiosarcoma
  • Chemotherapy
  • Concurrent chemoradiation
  • Paclitaxel
  • Radiation therapy


Dive into the research topics of 'Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma'. Together they form a unique fingerprint.

Cite this